Pfizer’s Talzenna Plus Xtandi FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

Oct 27, 2026 - 07:00
 0  0
NEW YORK--(BUSINESS WIRE) October 26, 2026 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) to the treatment of...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0